Topics Covered:
• Breakthroughs in metastatic bladder cancer treatment
• Perioperative immunotherapy strategies
• GFR limits for cisplatin eligibility
• Future directions in bladder cancer therapies
Dr. Vishesh Khanna from Oregon Health & Science University in conversation with Dr. Jonathan Rosenberg from Memorial Sloan Kettering Cancer Center
In this episode, Drs. Khanna & Rosenberg delve into the latest advancements in bladder cancer management, highlighting key breakthroughs such as the use of enfortumab vedotin and pembrolizumab in metastatic disease, which have significantly improved patient outcomes. They also discussed the evolving landscape of perioperative immunotherapy, the implications of GFR limits for cisplatin eligibility, and the potential future of bladder cancer treatments, including Nectin-4 targeted therapies and FGFR-3 specific inhibitors. Dr. Rosenberg shares his expert insights on managing recurrent disease and the importance of patient-centered care in treatment decisions.
